USA - NASDAQ:VNDA - US9216591084 - Common Stock
Overall VNDA gets a fundamental rating of 2 out of 10. We evaluated VNDA against 534 industry peers in the Biotechnology industry. While VNDA is still in line with the averages on profitability rating, there are concerns on its financial health. VNDA has a expensive valuation and it also scores bad on growth.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.71% | ||
| ROE | -13.76% | ||
| ROIC | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 94.4% | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.19 | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.25 | ||
| Quick Ratio | 3.23 | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A | 
4.32
-1.09 (-20.15%)
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 1.25 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 0.52 | ||
| P/tB | 0.68 | ||
| EV/EBITDA | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -10.71% | ||
| ROE | -13.76% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 94.4% | ||
| FCFM | N/A | 
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 13.98% | ||
| Cap/Sales | 0.55% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.25 | ||
| Quick Ratio | 3.23 | ||
| Altman-Z | 1.19 | 
ChartMill assigns a fundamental rating of 2 / 10 to VNDA.
ChartMill assigns a valuation rating of 0 / 10 to VANDA PHARMACEUTICALS INC (VNDA). This can be considered as Overvalued.
VANDA PHARMACEUTICALS INC (VNDA) has a profitability rating of 4 / 10.
The Earnings per Share (EPS) of VANDA PHARMACEUTICALS INC (VNDA) is expected to decline by -475.88% in the next year.